[go: up one dir, main page]

WO2005061534A3 - Improved tuberculosis vaccines - Google Patents

Improved tuberculosis vaccines Download PDF

Info

Publication number
WO2005061534A3
WO2005061534A3 PCT/DK2004/000907 DK2004000907W WO2005061534A3 WO 2005061534 A3 WO2005061534 A3 WO 2005061534A3 DK 2004000907 W DK2004000907 W DK 2004000907W WO 2005061534 A3 WO2005061534 A3 WO 2005061534A3
Authority
WO
WIPO (PCT)
Prior art keywords
vaccine
fusion polypeptide
bcg
pharmaceutical composition
tuberculosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DK2004/000907
Other languages
French (fr)
Other versions
WO2005061534A2 (en
Inventor
Dietrich Jes
Peter Andersen
Claus Aagaard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Statens Serum Institut SSI
Original Assignee
Statens Serum Institut SSI
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Statens Serum Institut SSI filed Critical Statens Serum Institut SSI
Publication of WO2005061534A2 publication Critical patent/WO2005061534A2/en
Anticipated expiration legal-status Critical
Publication of WO2005061534A3 publication Critical patent/WO2005061534A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention is related to an immunogenic composition, vaccine or pharmaceutical composition for preventing boosting or treating infection caused by a species of the tuberculosis complex (M. tuberculosis, M. bovis, M. africanum, M. microti). The immunogenic composition, vaccine or pharmaceutical composition comprise a fusion polypeptide, the units of the fusion polypeptide being M. tuberculosis antigens. Further, the invention is relates to the use of a vaccine comprising a fusion polypeptide sequence or nucleic acid sequence of the invention given at the same time as BCG, either mixed with BCG or administered separately at different sites or routes for preparing said immunogenic composition, vaccine, or pharmaceutical composition. Further, the invention is related to the use of a vaccine comprising a fusion polypeptide sequence or nucleic acid sequence given as BCG booster vaccine.
PCT/DK2004/000907 2003-12-23 2004-12-22 Improved tuberculosis vaccines Ceased WO2005061534A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200301942 2003-12-23
DKPA200301942 2003-12-23

Publications (2)

Publication Number Publication Date
WO2005061534A2 WO2005061534A2 (en) 2005-07-07
WO2005061534A3 true WO2005061534A3 (en) 2008-01-10

Family

ID=34707214

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2004/000907 Ceased WO2005061534A2 (en) 2003-12-23 2004-12-22 Improved tuberculosis vaccines

Country Status (1)

Country Link
WO (1) WO2005061534A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9226958B2 (en) 2010-10-01 2016-01-05 University Of Georgia Research Foundation, Inc. Use of Listeria vaccine vectors to reverse vaccine unresponsiveness in parasitically infected individuals
US9463227B2 (en) 2011-03-11 2016-10-11 Advaxis, Inc. Listeria-based adjuvants
CN106103471B (en) * 2014-01-09 2020-01-07 特兰斯吉恩股份有限公司 Fusion of heterooligomeric mycobacterial antigens

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ555907A (en) 2004-11-16 2009-12-24 Aeras Global Tb Vaccine Found Multivalent vaccines comprising recombinant viral vectors
CN100999550B (en) 2006-01-10 2010-10-06 中国人民解放军第三○九医院 Tubercle branch bacillus fusion protein and application thereof
EP2604695B1 (en) 2007-12-27 2022-11-16 Universität Zürich Replication-defective arenavirus vectors
EP2818178A1 (en) * 2008-01-11 2014-12-31 The Government of The United States of America as represented by The Secretary, Department of Health and Human Services Polypeptide vaccine and vaccination strategy against mycobacterium
US9650639B2 (en) 2008-05-19 2017-05-16 Advaxis, Inc. Dual delivery system for heterologous antigens
WO2009143167A2 (en) 2008-05-19 2009-11-26 Advaxis Dual delivery system for heterologous antigens
US20100015171A1 (en) * 2008-07-15 2010-01-21 Statens Serum Institute Vaccines comprising tb 10.4
WO2010127492A1 (en) * 2009-05-07 2010-11-11 华中科技大学 Recombinant bcg vaccine rbcg::xb
US10016617B2 (en) 2009-11-11 2018-07-10 The Trustees Of The University Of Pennsylvania Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
CN102154324B (en) * 2010-12-29 2012-11-28 兰州大学 Construction method of mycobacterium tuberculosis fusion protein Mtb 10.4-Hsp16.3, expression method thereof, purification method thereof and application thereof
WO2012125551A1 (en) 2011-03-11 2012-09-20 Advaxis Listeria-based adjuvants
JP2015511602A (en) 2012-03-12 2015-04-20 アドバクシス， インコーポレイテッド Inhibition of suppressor cell function after Listeria vaccine treatment
US9809801B2 (en) 2013-03-15 2017-11-07 Université De Genève Anti-mycobacterial vaccines
CN103698530B (en) * 2013-11-25 2015-08-19 广东体必康生物科技有限公司 The purposes of Mycobacterium tuberculosis albumen in the phthisical product of preparation diagnostic activities
RU2615440C2 (en) * 2015-05-25 2017-04-04 Илья Владимирович Духовлинов Fusion protein, dna, genetic construct, recombinant cell, fusion protein-based vaccine for tuberculosis prevention and treatment (versions)
KR102709729B1 (en) * 2020-12-04 2024-09-25 주식회사 제넥신 Pharmaceutical composition for preventing or treating tuberculosis

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999051748A2 (en) * 1998-04-07 1999-10-14 Corixa Corporation Fusion proteins of mycobacterium tuberculosis antigens and their uses
WO2000047227A2 (en) * 1999-02-09 2000-08-17 Powderject Vaccines, Inc. Mycobacterium tuberculosis, immunization
WO2001079274A2 (en) * 2000-04-19 2001-10-25 Statens Serum Institut Tuberculosis antigens and methods of use thereof
WO2003070187A2 (en) * 2002-02-15 2003-08-28 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
US6641814B1 (en) * 1997-04-02 2003-11-04 Statens Serum Institut Nucleic acids fragments and polypeptide fragments derived from M. tuberculosis

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6641814B1 (en) * 1997-04-02 2003-11-04 Statens Serum Institut Nucleic acids fragments and polypeptide fragments derived from M. tuberculosis
WO1999051748A2 (en) * 1998-04-07 1999-10-14 Corixa Corporation Fusion proteins of mycobacterium tuberculosis antigens and their uses
WO2000047227A2 (en) * 1999-02-09 2000-08-17 Powderject Vaccines, Inc. Mycobacterium tuberculosis, immunization
WO2001079274A2 (en) * 2000-04-19 2001-10-25 Statens Serum Institut Tuberculosis antigens and methods of use thereof
WO2003070187A2 (en) * 2002-02-15 2003-08-28 Corixa Corporation Fusion proteins of mycobacterium tuberculosis

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 16 August 2004 (2004-08-16), JIANG, SHAN ET AL: "Construction of the fused eukaryotic expression vector of Mycobacterium tuberculosis Ag85B- Ag85A double-antigens and its expression", XP002298005, retrieved from STN Database accession no. 2004:664103 *
DISI JUNYI DAXUE XUEBAO , 24(21), 1973-1975 CODEN: DJDXEG; ISSN: 1000-2790, 2003 *
SKJOT RIKKE LOUISE VINTHER ET AL: "Epitope mapping of the immunodominant antigen TB10.4 and the two homologous proteins TB10.3 and TB12.9, which constitute a subfamily of the esat-6 gene family.", INFECTION AND IMMUNITY. OCT 2002, vol. 70, no. 10, October 2002 (2002-10-01), pages 5446 - 5453, XP002322655, ISSN: 0019-9567 *
WEINRICH OLSEN A ET AL: "Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85B and ESAT-6", INFECTION AND IMMUNITY, AMERICAN SOCIETY FOR MICROBIOLOGY. WASHINGTON, US, vol. 69, no. 5, May 2001 (2001-05-01), pages 2773 - 2778, XP002285350, ISSN: 0019-9567 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9226958B2 (en) 2010-10-01 2016-01-05 University Of Georgia Research Foundation, Inc. Use of Listeria vaccine vectors to reverse vaccine unresponsiveness in parasitically infected individuals
US9463227B2 (en) 2011-03-11 2016-10-11 Advaxis, Inc. Listeria-based adjuvants
CN106103471B (en) * 2014-01-09 2020-01-07 特兰斯吉恩股份有限公司 Fusion of heterooligomeric mycobacterial antigens

Also Published As

Publication number Publication date
WO2005061534A2 (en) 2005-07-07

Similar Documents

Publication Publication Date Title
WO2006136162A3 (en) Tuberculosis vaccines comprising antigens expressed during the latent infection phase
WO2005061534A3 (en) Improved tuberculosis vaccines
WO2006032472A3 (en) Immunogenic composition for use in vaccination against staphylococcei
WO2008124647A3 (en) Immunogenic compositions comprising mycobacterium tuberculosis polypeptides and fusions thereof
DK1549338T3 (en) Polypeptide vaccines for broad protection against hypervirulent meningococcal lineages
WO2005097211A3 (en) Compositions as adjuvants to improve immune responses to vaccines and methods of use
WO2009095226A3 (en) NUCLEIC ACIDS COMPRISING FORMULA (NuGlXmGnNv)a AND DERIVATIVES THEREOF AS AN IMMUNOSTIMULATING AGENTS /ADJUVANTS
BRPI0409133B8 (en) stable pharmaceutical preparations comprising methylnaltrexone
DK0950068T3 (en) Collagen-binding protein compositions and methods of use
BR112015009070A2 (en) fusion protein or antigen cocktail; use of a fusion protein or cocktail of antigens; vaccine; and method for immunizing an animal, including a human, against tuberculosis caused by virulent microbacteria
BRPI0513390A (en) AIDS vaccines containing cmv / r nucleic acid constructs
WO2000062800A3 (en) Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
WO2007022151A3 (en) Immunization of avians by administration of non-replicating vectored vaccines
CA2656266A1 (en) Recombinant viral vaccine
Vordermeier et al. Improved immunogenicity of DNA vaccination with mycobacterial HSP65 against bovine tuberculosis by protein boosting
JP2008543890A5 (en)
ATE535600T1 (en) IDENTIFICATION OF THE VIRULENCE-ASSOCIATED REGION RD1 ALLOWING THE DEVELOPMENT OF IMPROVED M. MICROTI VACCINES
MY209484A (en) Cpg amphiphiles and uses thereof
WO2023104114A8 (en) Rna formulations and lipids
WO2008084072A3 (en) Protective proteins of s. agalactiae, combinations thereof and methods of using the same
DE60136928D1 (en) USE OF PLANT OIL BODY IN VACCINATE ADMINISTRATION SYSTEMS
WO2003037370A3 (en) Anthrax antigenic compositions
WO2009074861A3 (en) Improved vaccine
DE60336588D1 (en) IMPROVED ANTHRAXIMP AND METHOD OF DELIVERY
WO2009042538A3 (en) Immunogenic proteins from genome-derived outer membrane of leptospira and compositions and methods based thereon

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase